Skip to main content
Top
Published in: Digestive Diseases and Sciences 9/2009

01-09-2009 | REVIEW

Gastroesophageal Reflux Disease (GERD) and Irritable Bowel Syndrome (IBS)—Is It One Disease or an Overlap of Two Disorders?

Authors: Anita Gasiorowska, Choo Hean Poh, Ronnie Fass

Published in: Digestive Diseases and Sciences | Issue 9/2009

Login to get access

Abstract

Up to 79% of IBS patients report gastroesophageal reflux disease (GERD) symptoms, and up to 71% of GERD patients report irritable bowel syndrome (IBS) symptoms. There are two principal hypotheses for the common presence of IBS symptoms in GERD patients. The first theory suggests that GERD and IBS overlap in a significant number of patients. The second theory suggests that IBS-like symptoms are part of the spectrum of GERD manifestation. The first theory is supported by genetic studies and similarities in gastrointestinal sensory-motor abnormalities potentially due to general gastrointestinal disorder of smooth muscle or sensory afferents. The other theory is primarily supported by studies demonstrating improvement of IBS-like symptoms in GERD patients receiving anti-reflux treatment. The close relationship between GERD and IBS could be explained by either GERD affecting different levels of the GI tract or a high overlap rate between GERD and IBS due to similar underlying GI dysfunction.
Literature
1.
go back to reference Saito YA, Schoenfeld P, Locke GR 3rd. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol. 2002;97:1910–1915.PubMed Saito YA, Schoenfeld P, Locke GR 3rd. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol. 2002;97:1910–1915.PubMed
2.
go back to reference Talley NJ, Boyce P, Jones M. Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population. Gut. 1998;42:690–695.PubMed Talley NJ, Boyce P, Jones M. Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population. Gut. 1998;42:690–695.PubMed
3.
go back to reference Spiller R, Aziz Q, Creed F, et al. Clinical services committee of the British society of gastroenterology: guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 2007;56:1770–1798. doi:10.1136/gut.2007.119446.PubMedCrossRef Spiller R, Aziz Q, Creed F, et al. Clinical services committee of the British society of gastroenterology: guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 2007;56:1770–1798. doi:10.​1136/​gut.​2007.​119446.PubMedCrossRef
4.
go back to reference Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology. 1987;92:1282–1284.PubMed Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology. 1987;92:1282–1284.PubMed
6.
go back to reference Cheung TK, Lam KF, Hu WH, et al. Positive association between gastro-oesophageal reflux disease and irritable bowel syndrome in a Chinese population. Aliment Pharmacol Ther. 2007;25:1099–1104.PubMed Cheung TK, Lam KF, Hu WH, et al. Positive association between gastro-oesophageal reflux disease and irritable bowel syndrome in a Chinese population. Aliment Pharmacol Ther. 2007;25:1099–1104.PubMed
7.
go back to reference Hu WH, Wong WM, Lam CL, et al. Anxiety but not depression determines health care-seeking behaviour in Chinese patients with dyspepsia and irritable bowel syndrome: a population-based study. Aliment Pharmacol Ther. 2002;16:2081–2088. doi:10.1046/j.1365-2036.2002.01377.x. Hu WH, Wong WM, Lam CL, et al. Anxiety but not depression determines health care-seeking behaviour in Chinese patients with dyspepsia and irritable bowel syndrome: a population-based study. Aliment Pharmacol Ther. 2002;16:2081–2088. doi:10.​1046/​j.​1365-2036.​2002.​01377.​x.
9.
go back to reference Zimmerman B, Hershcovici T. Bowel symptoms in nonerosive gastroesophageal reflux disease: nature, prevalence, and relation to acid reflux. J Clin Gastroenterol. 2008;42:261–265.PubMed Zimmerman B, Hershcovici T. Bowel symptoms in nonerosive gastroesophageal reflux disease: nature, prevalence, and relation to acid reflux. J Clin Gastroenterol. 2008;42:261–265.PubMed
10.
go back to reference Agreus L, Svardsudd K, Talley NJ, Jones MP, Tibblin G. Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study. Am J Gastroenterol. 2001;96:2905–2914.PubMed Agreus L, Svardsudd K, Talley NJ, Jones MP, Tibblin G. Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study. Am J Gastroenterol. 2001;96:2905–2914.PubMed
15.
16.
go back to reference Kennedy TM, Jones RH, Hungin AP, O’Flanagan H, Kelly P. Irritable bowel syndrome, gastro-oesophageal reflux, and bronchial hyper-responsiveness in the general population. Gut. 1998;43:770–774.PubMed Kennedy TM, Jones RH, Hungin AP, O’Flanagan H, Kelly P. Irritable bowel syndrome, gastro-oesophageal reflux, and bronchial hyper-responsiveness in the general population. Gut. 1998;43:770–774.PubMed
17.
go back to reference De Vries DR, Van Herwaarden MA, Baron A, Smout AJ, Samsom M. Concomitant functional dyspepsia and irritable bowel syndrome decrease health-related quality of life in gastroesophageal reflux disease. Scand J Gastroenterol. 2007;42:951–956. doi:10.1080/00365520701204204.PubMedCrossRef De Vries DR, Van Herwaarden MA, Baron A, Smout AJ, Samsom M. Concomitant functional dyspepsia and irritable bowel syndrome decrease health-related quality of life in gastroesophageal reflux disease. Scand J Gastroenterol. 2007;42:951–956. doi:10.​1080/​0036552070120420​4.PubMedCrossRef
19.
go back to reference Fass R, Stanghellini V, Monnikes H. Baseline analysis of symptom spectrum in GERD clinical trial patients: result from ReQuest database. Gastroenterology. 2006;130:A629. Fass R, Stanghellini V, Monnikes H. Baseline analysis of symptom spectrum in GERD clinical trial patients: result from ReQuest database. Gastroenterology. 2006;130:A629.
20.
go back to reference Guillemot F, Ducrotte P, Bueno L. Prevalence of functional gastrointestinal disorders in a population of subjects consulting for gastroesophageal reflux disease in general practice. Gastroenterol Clin Biol. 2005;29:243–246. doi:10.1016/S0399-8320(05)80756-0.PubMed Guillemot F, Ducrotte P, Bueno L. Prevalence of functional gastrointestinal disorders in a population of subjects consulting for gastroesophageal reflux disease in general practice. Gastroenterol Clin Biol. 2005;29:243–246. doi:10.​1016/​S0399-8320(05)80756-0.PubMed
24.
go back to reference Talley NJ. A unifying hypothesis for the functional gastrointestinal disorders: really multiple diseases or one irritable gut? Rev Gastroenterol Disord. 2006;6:72–78.PubMed Talley NJ. A unifying hypothesis for the functional gastrointestinal disorders: really multiple diseases or one irritable gut? Rev Gastroenterol Disord. 2006;6:72–78.PubMed
26.
go back to reference Lembo A, Zaman M, Jones M, Talley NJ. Influence of genetics on irritable bowel syndrome, gastro-oesophageal reflux and dyspepsia: a twin study. Aliment Pharmacol Ther. 2007;25:1343–1350.PubMed Lembo A, Zaman M, Jones M, Talley NJ. Influence of genetics on irritable bowel syndrome, gastro-oesophageal reflux and dyspepsia: a twin study. Aliment Pharmacol Ther. 2007;25:1343–1350.PubMed
28.
30.
go back to reference Rubenstein JH, Nojkov B, Korsnes S, et al. Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26:443–453.PubMed Rubenstein JH, Nojkov B, Korsnes S, et al. Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26:443–453.PubMed
31.
go back to reference Trimble KC, Farouk R, Pryde A, Douglas S, Heading RC. Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity. Dig Dis Sci. 1995;40:1607–1613. doi:10.1007/BF02212678.PubMedCrossRef Trimble KC, Farouk R, Pryde A, Douglas S, Heading RC. Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity. Dig Dis Sci. 1995;40:1607–1613. doi:10.​1007/​BF02212678.PubMedCrossRef
34.
go back to reference Jung HK, Halder S, McNally M, et al. Overlap of gastro-oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population. Aliment Pharmacol Ther. 2007;26:453–461.PubMedCrossRef Jung HK, Halder S, McNally M, et al. Overlap of gastro-oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population. Aliment Pharmacol Ther. 2007;26:453–461.PubMedCrossRef
35.
go back to reference Nojkov B, Rubenstein JH, Adlis SA, et al. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2008;27:473–482.PubMedCrossRef Nojkov B, Rubenstein JH, Adlis SA, et al. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2008;27:473–482.PubMedCrossRef
37.
go back to reference Kountouras J, Chatzopoulos D, Zavos C, Boura P, Venizelos J, Kalis A. Efficacy of trimebutine therapy in patients with gastroesophageal reflux disease and irritable bowel syndrome. Hepatogastroenterology. 2002;49:193–197.PubMed Kountouras J, Chatzopoulos D, Zavos C, Boura P, Venizelos J, Kalis A. Efficacy of trimebutine therapy in patients with gastroesophageal reflux disease and irritable bowel syndrome. Hepatogastroenterology. 2002;49:193–197.PubMed
38.
go back to reference Stanghellini V, Armstrong D, Mönnikes H, Berghöfer P, Gatz G, Bardhan KD. Determination of ReQuest-based symptom thresholds to define symptom relief in GERD clinical studies. Digestion. 2007;75:55–61. doi:10.1159/000101083.PubMedCrossRef Stanghellini V, Armstrong D, Mönnikes H, Berghöfer P, Gatz G, Bardhan KD. Determination of ReQuest-based symptom thresholds to define symptom relief in GERD clinical studies. Digestion. 2007;75:55–61. doi:10.​1159/​000101083.PubMedCrossRef
39.
go back to reference Glatzel D, Abdel-Quader M, Gatz G, Pfaffenberger B. Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse. Digestion. 2007;75:69–78. doi:10.1159/000101085.PubMedCrossRef Glatzel D, Abdel-Quader M, Gatz G, Pfaffenberger B. Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse. Digestion. 2007;75:69–78. doi:10.​1159/​000101085.PubMedCrossRef
40.
go back to reference Monnikes H, Pfaffenberger B, Gatz G, Hein J, Bardhan KD. Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole. Digestion. 2007;75:62–68.PubMed Monnikes H, Pfaffenberger B, Gatz G, Hein J, Bardhan KD. Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole. Digestion. 2007;75:62–68.PubMed
41.
go back to reference Stanghellini V. ReQuest: new dimensions in the assessment and management of GERD. Drugs Today (Barc). 2005;41:7–11. Stanghellini V. ReQuest: new dimensions in the assessment and management of GERD. Drugs Today (Barc). 2005;41:7–11.
Metadata
Title
Gastroesophageal Reflux Disease (GERD) and Irritable Bowel Syndrome (IBS)—Is It One Disease or an Overlap of Two Disorders?
Authors
Anita Gasiorowska
Choo Hean Poh
Ronnie Fass
Publication date
01-09-2009
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 9/2009
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-008-0594-2

Other articles of this Issue 9/2009

Digestive Diseases and Sciences 9/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.